Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
ABBV | NYSE | USD | Real-time | |
0QCV | London | EUR | Real-time | |
ABBV | BIVA | MXN | Delayed | |
ABBV | Mexico | MXN | Delayed | |
1ABBV | Milan | EUR | Real-time | |
4AB | TradeGate | EUR | Delayed | |
4AB | Frankfurt | EUR | Delayed | |
ABBV34 | B3 | BRL | Delayed | |
ABBV | Vienna | EUR | Real-time |
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
---|---|---|---|---|---|
Moving Averages | Buy | Buy | Neutral | Neutral | Buy |
Technical Indicators | BUY | Strong Buy | Strong Buy | Strong Sell | Strong Buy |
Summary | Buy | Strong Buy | Buy | Sell | Strong Buy |
Filter Table By:
Pattern | Timeframe | Reliability | Candles Ago | Candle Time | |
---|---|---|---|---|---|
Emerging Patterns | |||||
Engulfing Bearish | 30 | Current | |||
Completed Patterns | |||||
Engulfing Bearish | 1D | 1 | Apr 19, 2024 | ||
Three Black Crows | 15 | 1 | Apr 22, 2024 16:15 | ||
Two Crows | 15 | 2 | Apr 22, 2024 16:00 |
Exchange | Last | Bid | Ask | Volume | Change % | Currency | Time | ||
---|---|---|---|---|---|---|---|---|---|
NYSE | 167.89 | 166.25 | 168.00 | 5,567,396 | +0.89% | USD | |||
London | 168.30 | 159.82 | 176.64 | 2,456,696 | +1.78% | EUR | |||
BIVA | 2,880.00 | 0.00 | 0.00 | 0 | 0.00% | MXN | |||
Mexico | 2,803.98 | 2,803.98 | 3,050.00 | 6 | -0.53% | MXN | |||
Milan | 157.60 | 0.00 | 0.00 | 37 | +1.39% | EUR | |||
TradeGate | 157.46 | 157.54 | 158.36 | 0 | 0.00% | EUR | |||
Frankfurt | 156.88 | 156.88 | 158.38 | 10 | -0.04% | EUR | |||
B3 | 54.40 | 52.45 | 55.90 | 50 | +0.59% | BRL | |||
Vienna | 164.70 | 161.00 | 164.70 | 0 | +0.00% | EUR |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
---|---|---|---|---|---|---|---|---|---|
IAG | 175.20 | 176.40 | 170.10 | +5.70 | +3.36% | 22.14M | 22/04 | ||
HSBC | 666.50 | 669.80 | 653.30 | +20.30 | +3.14% | 22.18M | 22/04 | ||
Lloyds Banking | 51.14 | 51.72 | 51.10 | +0.22 | +0.43% | 138.33M | 22/04 | ||
Rolls-Royce Holdings | 406.30 | 406.80 | 398.90 | +10.80 | +2.73% | 20.37M | 22/04 | ||
Reliance Industries Ltd | 72.10 | 72.20 | 71.00 | +1.10 | +1.55% | 93.20K | 22/04 | ||
Barclays | 189.18 | 190.04 | 186.84 | +3.34 | +1.80% | 40.31M | 22/04 | ||
Vodafone Group PLC | 69.620 | 69.942 | 67.545 | +2.620 | +3.91% | 69.12M | 22/04 | ||
Legal & General | 250.40 | 252.40 | 247.00 | +5.80 | +2.37% | 13.02M | 22/04 | ||
BP | 522.50 | 523.80 | 514.90 | +7.60 | +1.48% | 31.67M | 22/04 | ||
EasyJet | 547.20 | 553.20 | 531.80 | +12.00 | +2.24% | 4.46M | 22/04 |
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn’s disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Read MoreAre you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review